Lundbeck and Genmab work on antibodies for central nervous system

10/13/2010 | Reuters

Genmab stands to receive as much as $53.5 million, including $10.4 million upfront, from H. Lundbeck in a deal to develop human antibodies to treat diseases affecting the central nervous system. The collaboration provides Lundbeck access to Genmab's human-antibody technology UltiMab, allowing it "to pursue valuable [central nervous system] targets otherwise not accessible."

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY